



UNITED STATES
NUCLEAR REGULATORY COMMISSION
REGION I
475 ALLENDALE ROAD
KING OF PRUSSIA, PENNSYLVANIA 19406-1415

April 25, 2008

Docket No. 03003347
Control No. 142327

License No. 45-10831-02

Susan A. MacLeod
Executive Vice President/Administrator
Maryview Medical Center
3636 High Street
Portsmouth, VA 23707

SUBJECT: MARYVIEW MEDICAL CENTER, LICENSE AMENDMENT, CONTROL NO.
142327

Dear Ms. MacLeod:

This refers to your license amendment request. Enclosed with this letter is the amended license adding the iodine-125 source model, as referenced in the Sealed Source and Device Registry. The palladium-103 source was not added to your NRC license, since this source is regulated by the State of Virginia. The State should be contacted for licensing of this source model.

Please review the enclosed document carefully and be sure that you understand and fully implement all the conditions incorporated into the amended license. If there are any errors or questions, please notify the U.S. Nuclear Regulatory Commission, Region I Office, Licensing Assistance Team, (610) 337-5239, so that we can provide appropriate corrections and answers.

An environmental assessment for this action is not required, since this action is categorically excluded under 10 CFR 51.22(c)(14).

Current NRC regulations and guidance are included on the NRC's website at www.nrc.gov; select **Nuclear Materials; Medical, Academic, and Industrial Uses of Nuclear Material**; then **Regulations, Guidance, and Communications**. You may also obtain these documents by contacting the Government Printing Office (GPO) toll-free at 1-866-512-1800. The GPO is open from 7:00 a.m. to 8:00 p.m. EST, Monday through Friday (except Federal holidays).

Thank you for your cooperation.

Sincerely,

Original signed by Penny Lanzisera

Penny Lanzisera
Senior Health Physicist
Medical Branch
Division of Nuclear Materials Safety

S. MacLeod
Maryview Medical Center

2

Enclosure:
Amendment No. 51

cc:
Michael Ho, M.D., Radiation Safety Officer

DOCUMENT NAME: C:\FileNet\ML081160208.wpd

SUNSI Review Complete: PLanzisera

After declaring this document "An Official Agency Record" it will be released to the Public.

To receive a copy of this document, indicate in the box: "C" = Copy w/o attach/encl "E" = Copy w/ attach/encl "N" = No copy

OFFICE	DNMS/RI	<input checked="" type="checkbox"/> N	DNMS/RI	<input type="checkbox"/>	DNMS/RI	<input type="checkbox"/>	<input type="checkbox"/>
NAME	PLanzisera/PL						
DATE	4-25-08						

OFFICIAL RECORD COPY

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Maryview Medical Center</p> <p>2. 3636 High Street Portsmouth, Virginia 23707</p>	<p>In accordance with the letter dated April 10, 2008,</p> <p>3. License number 45-10831-02</p> <p>is amended in its entirety to read as follows:</p> <hr/> <p>4. Expiration date December 31, 2015</p> <hr/> <p>5. Docket No. 030-03347 Reference No.</p>
---	--

<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p> <p>D. Iodine 125 permitted by 10 CFR 35.400</p> <p>E. Strontium 90</p> <p>F. Gadolinium 153</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p> <p>D. Sealed Sources (SourceTech Medical Model STM 1251; North American Scientific, Inc. Model 3631)</p> <p>E. Sealed Sources (Nuclear Enterprises Model 2503/3; Amersham Model SIC.7)</p> <p>F. Sealed Sources (North American Scientific Model 3601)</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As needed</p> <p>B. As needed</p> <p>C. 2 curies</p> <p>D. 1.5 curies</p> <p>E. 10 millicuries</p> <p>F. 500 millicuries</p>
--	--	--

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
45-10831-02

Docket or Reference Number
030-03347

Amendment No. 51

9. Authorized use:

- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
- B. Any imaging and localization study permitted by 10 CFR 35.200.
- C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300, for which the patient can be released under the provisions of 10 CFR 35.75.
- D. Any manual brachytherapy procedure permitted by 10 CFR 35.400, for which the patient can be released under the provisions of 10 CFR 35.75.
- E. Calibration of the licensee's instruments.
- F. Storage and possession only with intent to dispose.

CONDITIONS

- 10. Licensed material may be used or stored only at the licensee's facilities located at 3636 High Street, Portsmouth, Virginia.
- 11. The Radiation Safety Officer for this license is Michael Ho, M.D.
- 12. Licensed material is only authorized for use by, or under the supervision of:
 - A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
 - B. The following individuals are authorized users for medical use as indicated:

Authorized Users

Material and Use

Stephen Carr, M.D.	35.100; 35.200; 35.300, except thyroid carcinoma
Nripendra Devanath, M.D.	35.100; 35.200; 35.300, except thyroid carcinoma
Patsy J. Loiacono, M.D.	35.100; 35.200; 35.300, except thyroid carcinoma
David Weaver, M.D.	35.100; 35.200; 35.300, except thyroid carcinoma
Ronald L. King, M.D.	35.100; 35.200; 35.300, except thyroid carcinoma
Robert A. Woolfit, M.D.	35.100; 35.200; 35.300, except thyroid carcinoma
Susan McKenzie, M.D.	35.100; 35.200; 35.300, except thyroid carcinoma
Hussein Aboulatta, M.D.	35.100; 35.200
Shoaib Bakht, M.D.	35.100; 35.200
John V. Whitbeck, M.D.	35.100; 35.200

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
45-10831-02

Docket or Reference Number
030-03347

Amendment No. 51

<u>Authorized Users</u>	<u>Material and Use</u>
Apurva M. Patel, M.D.	35.100; 35.200
Emanuel Stein, M.D.	35.100; 35.200
Lamar H. Smith, M.D.	35.100; 35.200; 35.300, except thyroid carcinoma
Michael Ho, M.D.	35.100; 35.200
Lori Keith Taylor, M.D.	35.100; 35.200
William C. Feldmann, M.D.	35.100; 35.200
John C. Agola, M.D.	35.100; 35.200
John F. Donnal, M.D.	35.100; 35.200
Bhavdeep K. Gupta, M.D.	35.200
Janice Roman, M.D.	35.300; 35.400
Edward M. Lynch, M.D.	35.100; 35.200
Mark S. Sinesi, M.D.	35.300; 35.400
Christopher C. Sinesi, M.D.	35.300; 35.400
Dae Been Chough, M.D.	35.200
Preston L. Judson, M.D.	35.100; 35.200
Scott Seth Williams, M.D.	35.300; 35.400
James E. Anderson, M.D.	35.100; 35.200
Bernard Tisdale, M.D.	35.300; 35.400
Judith G. Blevins, M.D.	35.300; 35.400
Biral Amin, M.D.	Oral administration of sodium iodide I-131; Parenteral administration of any beta emitter, or a photon-emitting radionuclide with a photon energy less than 150 keV; 35.400

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
45-10831-02

Docket or Reference Number
030-03347

Amendment No. 51

C. The following individuals are authorized users for non-medical uses as indicated:

Users

Material and Use

Leland Kirkland, Ph.D.

Strontium-90 for calibration of instruments

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
14. For sealed sources not associated with 10 CFR Part 35 use, the following conditions apply:
- A. Sealed sources shall be tested for leakage and/or contamination at intervals not to exceed six months or at the intervals specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or under equivalent regulations of an Agreement State.
 - B. In the absence of a certificate from a transferor indicating that a leak test has been made within the intervals specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or under equivalent regulations of an Agreement State, prior to the transfer, a sealed source received from another person shall not be put into use until tested and the test results received.
 - C. Sealed sources need not be tested if they contain only hydrogen-3; or they contain only a radioactive gas; or the half-life of the isotope is 30 days or less; or they contain not more than 100 microcuries of beta- and/or gamma-emitting material or not more than 10 microcuries of alpha-emitting material.
 - D. Sealed sources need not be tested if they are in storage and are not being used; however, when they are removed from storage for use or transferred to another person and have not been tested within the required leak test interval, they shall be tested before use or transfer. No sealed source shall be stored for a period of more than 10 years without being tested for leakage and/or contamination.
 - E. The leak test shall be capable of detecting the presence of 0.005 microcurie (185 becquerels) of radioactive material on the test sample. If the test reveals the presence of 0.005 microcurie (185 becquerels) or more of removable contamination, a report shall be filed with the U.S. Nuclear Regulatory Commission in accordance with 10 CFR 30.50(c)(2), and the source shall be removed immediately from service and decontaminated, repaired, or disposed of in accordance with Commission regulations.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
45-10831-02Docket or Reference Number
030-03347

Amendment No. 51

- F. Tests for leakage and/or contamination, limited to leak test sample collection, shall be performed by the licensee or by other persons specifically licensed by the U.S. Nuclear Regulatory Commission or an Agreement State to perform such services. The licensee is not authorized to perform the analysis; analysis of leak test samples must be performed by persons specifically licensed by U.S. Nuclear Regulatory Commission or an Agreement State to perform such services.
- G. Records of leak test results shall be kept in units of microcuries and shall be maintained for 5 years.
15. The licensee shall conduct a physical inventory every six months, or at other intervals approved by the U.S. Nuclear Regulatory Commission, to account for all sources and/or devices received and possessed under the license. Records of inventories shall be maintained for 5 years from the date of each inventory and shall include the radionuclides, quantities, manufacturer's name and model numbers, and the date of the inventory.
16. Sealed sources or detector cells containing licensed material shall not be opened or sources removed from source holders by the licensee.
17. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
45-10831-02Docket or Reference Number
030-03347

Amendment No. 51

18. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Letter dated September 29, 1995
 - B. Application dated June 28, 2005 (ML051920331)
 - C. Letter dated September 1, 2005 (ML052450130)
 - D. Letter dated December 22, 2005 (ML053610098)



For the U.S. Nuclear Regulatory Commission

Date April 22, 2008

By

Original signed by Penny LanziseraPenny Lanzisera
Medical Branch
Division of Nuclear Materials Safety
Region I
King of Prussia, Pennsylvania 19406